Potent

Moderate Potency

Potent

First line for patients with type 2 diabetes where remote upload to Diasend is not required.

1st Line Choice for people with Type1 and Type2 Diabetes

1st Line for people with Type2 Diabetes

High dose ICS for asthma only - please take advice from secondary care.

Beclometasone diproprionate (Clipper) is an additional option after an oral aminosalicylate in mild to moderate left sided or extensive ulcerative colitis (as per NICE CG for ulcerative colitis). It may be considered for patients in whom the use of prednisolone would best be avoided. GPs need to be aware of the 4 week course and the dosing of 5mg daily for Beclometasone diproprionate and may wish to consider seeking advice from the IBD team when prescribing this steroid.

2nd line for people with Type2 Diabetes

Potent

Meter no longer made - OK to prescribe for existing users

Potent

High dose ICS for asthma only - please take advice from secondary care.

for patients with significant swallowing difficulties unable to take ANY medicine in a solid dose formulation. The strict administration requirements for Binosto are the same as for the standard alendronate. Binosto is considerably more expensive than the preferred standard alendronate formulation.

NICE recommends as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode

NICE recommends as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode

NICE recommends as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode

For use only in adult patients with moderate to severe persistent facial erythema associated with rosacea. It is not indicated for symptoms of flushing and GPs may wish to consider seeking dermatology advice (eg email communication) prior to prescribing to ensure appropriate use. Its use is contraindicated in patients receiving monoamine oxidase inhibitor therapy or tricyclic or tetracyclic antidepressants

Should be used only by doctors with anaesthetic training and should not be administered parenterally unless resuscitation equipment is available

Administered BD

Administered BD

Potent

Simbrinza – a combination of brinzolamide and brimonidine– is accepted onto the formulary for decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

1st Line for people with Type 1 Diabetes who test for Ketones

Administered OD or BD

Administered BD

Brivaracetam is accepted onto the formulary for adjunctive treatment of focal onset seizures, with or without secondary generalisation, in adults, adolescents and children from 4 years of age with epilepsy. It will be initiated by the specialist.

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

Brivaracetam is accepted onto the formulary for adjunctive treatment of focal onset seizures, with or without secondary generalisation, in adults, adolescents and children from 4 years of age with epilepsy. It will be initiated by the specialist.

Brivaracetam is accepted onto the formulary for adjunctive treatment of focal onset seizures, with or without secondary generalisation, in adults, adolescents and children from 4 years of age with epilepsy. It will be initiated by the specialist.

Brivaracetam is accepted onto the formulary for adjunctive treatment of focal onset seizures, with or without secondary generalisation, in adults, adolescents and children from 4 years of age with epilepsy. It will be initiated by the specialist.

Brivaracetam is accepted onto the formulary for adjunctive treatment of focal onset seizures, with or without secondary generalisation, in adults, adolescents and children from 4 years of age with epilepsy. It will be initiated by the specialist.

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

This item is only to be prescribed by 'We Are With You' (WAWY) Please see Implementation of Buvidal document under important local documents tab above

For use in migraine, see section 4.7.2 Prophylaxis of Migraine

For use in migraine, see section 4.7.2 Prophylaxis of Migraine

High dose ICS for asthma only - please take advice from secondary care.